Technical Analysis for LQDA - Liquidia Technologies, Inc.

Grade Last Price % Change Price Change
grade F 15.97 -3.97% -0.66
LQDA closed down 3.97 percent on Friday, February 15, 2019, on 89 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical LQDA trend table...

Date Alert Name Type % Chg
Feb 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 15 Bollinger Band Squeeze Range Contraction 0.00%
Feb 15 Narrow Range Bar Range Contraction 0.00%
Feb 15 NR7 Range Contraction 0.00%
Feb 15 BB Squeeze + Upper Band Touch Range Contraction 0.00%
Feb 15 Inside Day Range Contraction 0.00%
Feb 15 Upper Bollinger Band Touch Strength 0.00%
Feb 14 Crossed Above 20 DMA Bullish -3.97%
Feb 14 Bollinger Band Squeeze Range Contraction -3.97%
Feb 14 Earnings Movers Other -3.97%

Older signals for LQDA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Health Biopharmaceutical Life Sciences Pharmaceutical Pharmaceutical Industry Pain Medication Clinical Trial Pulmonary Arterial Hypertension Two River Treprostinil
Is LQDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 38.46
52 Week Low 10.52
Average Volume 28,841
200-Day Moving Average 0.0
50-Day Moving Average 18.3666
20-Day Moving Average 14.543
10-Day Moving Average 14.86
Average True Range 1.6937
ADX 23.22
+DI 18.1489
-DI 15.8475
Chandelier Exit (Long, 3 ATRs ) 13.5589
Chandelier Exit (Short, 3 ATRs ) 17.6812
Upper Bollinger Band 16.0602
Lower Bollinger Band 13.0258
Percent B (%b) 0.97
BandWidth 20.865021
MACD Line -0.7497
MACD Signal Line -1.1948
MACD Histogram 0.4451
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.93
Resistance 3 (R3) 17.04 16.82 16.77
Resistance 2 (R2) 16.82 16.58 16.77 16.72
Resistance 1 (R1) 16.40 16.43 16.29 16.29 16.66
Pivot Point 16.18 16.18 16.13 16.13 16.18
Support 1 (S1) 15.76 15.94 15.65 15.65 15.28
Support 2 (S2) 15.54 15.79 15.49 15.22
Support 3 (S3) 15.12 15.54 15.17
Support 4 (S4) 15.01